Skip to main content

Table 1 Dose-dependent inhibitory effects resulting from cumulative doses of baclofen versus repeated doses of saline on visceromotor responses to urinary bladder distension measured as % baseline AUC

From: Systemic and intrathecal baclofen produce bladder antinociception in rats

  Pretreaments
NBI No NBI   NBI No NBI
Plus ABI No ABI   Plus ABI No ABI
Cumulative dose IP n = 8 n = 8 Repeated dose IP n = 8 n = 8
Baclofen 1 mg/kg 115.2 ± 23.4 113.0 ± 15.2 Saline 1st 142.5 ± 16.8 154.6 ± 9.1
Baclofen 2 mg/kg 101.5 ± 25.4 96.0 ± 17.8* Saline 2nd 145.9 ± 19.5 156.6 ± 8.4
Baclofen 4 mg/kg 57.5 ± 22.2* 67.9 ± 15.3* Saline 3rd 145.5 ± 18.0 142.9 ± 11.2
Baclofen 8 mg/kg 17.2 ± 6.8* 21.0 ± 9.5* Saline 4th 156.7 ± 19.8 141.8 ± 8.8
Cumulative dose IT n = 8 n = 8 Repeated dose IT n = 6 n = 6
Baclofen 10 ng 104.6 ± 5.3 119.4 ± 16.4 Saline 1st 110.8 ± 9.3 111.2 ± 10.2
Baclofen 20 ng 82.0 ± 7.2 89.2 ± 12.0 Saline 2nd 88.3 ± 18.2 94.9 ± 9.9
Baclofen 40 ng 49.9 ± 11.8* 64.7 ± 15.8* Saline 3rd 114.2 + 24.2 112.0 ± 14.9
Baclofen 80 ng 24.5 ± 8.3* 30.5 ± 15.1* Saline 4th 114.0 ± 25.1 121.1 ± 15.9
Baclofen 160 ng 9.9 ± 4.6* 9.1 ± 9.1* Saline 5th 93.7 ± 21.1 142.0 ± 22.7
  1. Data represents mean ± SEM
  2. AUC indicates Area-Under-the-Curve, a statistic describing vigor of visceromotor responses to graded urinary Bladder distension (10–60 mm Hg, 20 s). See text for more complete description
  3. NBI neonatal bladder inflammation—pretreatment as defined in section “Neonatal bladder inflammation (NBI)” of text; ABI adult bladder inflammation—pretreatment as defined in section “Adult bladder inflammation (ABI)” of text, mcg microgram, ng nanogram, kg kilogram, IP intraperitoneal, IT intrathecal
  4. *Statistically significant difference from Saline-dosed rats in same Pretreatment category (p < 0.05, unpaired t-test)